Alpha Tau Medical

19/11/2025

Receiving a diagnosis of pancreatic cancer can be devastating, and all too often it arrives at a stage where surgical removal is no longer an option. This is because pancreatic cancer is frequently silent until it progresses; by the time symptoms appear, the disease has often spread beyond the pancreas. Yet, despite its grim reputation, there are promising advances in both detection and treatment - from refined chemotherapy to radiation innovations and participation in clinical trials.

Dr. Mark D'Andrea, a leading radiation oncologist and principal investigator of the Alpha DaRT pancreatic cancer trial in the U.S., recently spoke with the daily radio talk-show Hello Houston, where he shared insights about the disease and possible treatments.

Read the full article on our website:

Understanding Pancreatic CancerReceiving a diagnosis of pancreatic cancer can be devastating, and all too often it arrives at a stage where surgical removal is no longer an option. This is because pancreatic cancer is frequently silent until it progresses; by the time symptoms appear, the disease ha...

11/11/2025

Alpha tau medical today announced that CFO Raphi Levy will participate at the Global Healthcare Conference in London on November 18-19, 2025.

📈 Event: Jefferies Global Healthcare Conference

🤝 Format: 1X1 Investor meetings

📅 Date: November 18-19, 2025

📍Location: London

To read the full announcement, please read:

JERUSALEM, November 11, 2025 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will participate at the Jefferies Global Healthcare Conference in London ...

09/11/2025

It’s not easy to catch a busy engineer like Yoav Roa, but after a month of trying, we finally managed to sit him down for a quick .

Yoav has been with Alpha TAU Medical for four and a half years, after joining us from Intel. “It’s the best professional decision I’ve ever made,” he says with a smile, recalling how, during his first year here, he commuted two and a half hours each way by bus from Yeruham.

At Alpha TAU, Yoav, who is a mechanical engineer with a degree from Ben-Gurion University, serves as the R&D Project Manager for our ongoing (glioblastoma) project, a role he’s held for the past four years.

“We develop applicators for the company’s treatments,” he explains. “Some of our projects focus on improving existing systems, while others involve adapting applicators for new indications.”

Yoav told us how he first found his way to Alpha Tau: “I heard about the company from a friend and decided it was the opportunity of a lifetime. Before that, I worked as a data analyst - great conditions, comfortable job - but I wanted to do something that truly excited me. Joining Alpha TAU was like fulfilling a dream. I love that what we do here actually makes a difference in people’s lives.”

One moment that stands out vividly for him happened during an unexpected team meeting: “Someone suddenly walked into the office, I didn’t even know who he was, and started telling us about his experience with our treatment for lip cancer. He said there wasn’t even a mark left from the tumor that used to be there*. At that moment, it felt like all our hard work was worth it.”

Outside of work, Yoav, whose family roots are in Ecuador and Chile, spends most of his time raising his two young children. When he finds a few spare hours, he enjoys painting, volunteering with Magen David Adom, and rappelling.

* No certain results or outcomes can be known or guaranteed and results may vary.
* Alpha DaRT is available only through clinical trials.

05/11/2025

In the small town of Cooperstown, New York, Bassett Healthcare Network has successfully delivered its first AlphaDaRT® treatment as part of Alpha TAU’s national IMPACT study. The treatment, which was led by Dr. Timothy Korytko, has already received notable media coverage in The Daily Star and Yahoo News.

At Alpha Tau Medical, we are committed to providing solutions for patients who have no other treatment options. From the West Coast of California to the East Coast of New York and Florida, from Cooperstown to Canada and France, Alpha DaRT® is reaching patients in every corner, offering new hope even in the most challenging cases.

Our vision is clear: every patient deserves access to advanced treatment, no matter where they live.

*Alpha DaRT is available only through clinical trials.

Read more in The Daily Star: https://lnkd.in/dUdt3VKd

And on Yahoo! News: https://lnkd.in/di3kussQ

This link will take you to a page that’s not on LinkedIn

02/11/2025

"I am extremely patient-focused, so for this data to show potential quality of life improvement and potential extension of life is exciting.”

Opening November - Month - with an insightful interview regarding data from our research, with Dr. Harold Jacob, who leads our pancreatic cancer trials at Hadassah Medical Center.

Over the past few years, Alpha TAU has dedicated significant resources to advancing pancreatic cancer research - recognizing it as one of the deadliest and most silent cancers, often diagnosed late and with very limited treatment options. Pancreatic cancer has one of the lowest survival rates among major cancers, underscoring the urgent need for new therapeutic approaches.

As our studies progress in both Israel and the United States, Dr. Jacob sat down with us to address some of the most pressing questions about our work in this area: What concerns do patients typically raise regarding Alpha DaRT treatment? Who is this research intended for? How are the results so far? What are the potential benefits for patients?

Curious to learn more? Read the full interview on our website (link in the first comment).

*The Alpha DaRT® technology is currently available only as part of clinical trials.
Ac

27/10/2025

Loving how our new manufacturing facility looks on a sunny New Hampshire day. Shiny.

Design and architecture: Studio 26 Design Collaborative, LLC

Photos by Ofer Magen

22/10/2025

Green Light! 🟢

Today, we are not the same company we were last week.

We are now a licensed manufacturer of Radium-224 in the State of New Hampshire - a major step forward in our mission to bring Alpha DaRT® closer to US and North-American patients!

Our new commercial-scale manufacturing facility in Hudson has officially received its license from the Bureau of Public Health Protection. This achievement allows us to move ahead with equipping, verification, and validation - all leading toward the start of treatment manufacturing in 2026 in the U.S.

This milestone is important because it demonstrates that we meet building and procedural quality standards that very few companies of our size achieve. We have employed the most advanced technologies available to produce this material, ensuring the highest quality product - ready for patients, as well as the physicians and clinics we collaborate with.

This achievement reflects our commitment to the highest standards of safety, quality, and innovation. It also moves us closer to realizing our vision of making cutting-edge alpha more accessible to patients around the world.

A heartfelt thank you to our operations and engineering teams, our partners at A&M Construction Co., and the New Hampshire Department of Health and Human Services for their collaboration and support along the way.

21/10/2025

Alpha Tau Medical announced today that it has secured a material license from the State of New Hampshire Bureau of Public Health Protection, Radiological Health Section, following completion of the first phase of construction of its -scale manufacturing facility in Hudson, New Hampshire.

To read the full announcement :

- Receipt of critical license marks significant milestone for first commercial-scale manufacturing facility for Alpha DaRT®, the innovative alpha-radiation cancer therapy designed for potent and conformal tumor irradiation -- License paves way for introduction of radioactive material and continued ...

15/10/2025

This October, we stand with patients, survivors, and everyone affected by breast cancer.

Each year, millions of people - mostly women - are diagnosed with this disease. Early detection through regular screening can save lives, yet too many cases are still found too late.

At Alpha TAU Medical, our mission is to help people fight cancer - through treatment, awareness, and education.

Take a moment to schedule your screening, or remind someone you love to do the same. 💗

09/10/2025

Trigger warning: we trigger the immune system.

This year’s Nobel Prize honored the scientists who uncovered the immune system’s natural “brakes.” - Shimon Sakaguchi, Mary Brunkow and Fred Ramsdell.

They discovered how regulatory T cells and the FOXP3 gene help control immune tolerance - keeping the immune system from attacking the body’s own tissues.

But in many cancers, those same brakes prevent the body from recognizing and fighting tumors.

Alpha DaRT®, our diffusing alpha-emitters radiation therapy, has shown pre-clinical evidence of lifting that suppression - triggering local and systemic immune responses that may complement .

And that’s exactly where the promise of comes in. By pairing Alpha DaRT with immune checkpoint inhibitors, we’ve seen encouraging pre-clinical results suggesting that localized alpha radiation could help “unlock” the tumor, enabling the immune system - and systemic therapies - to act more effectively. It’s an approach that could redefine how we think about synergy between localized radiotheraputics and systemic treatments.

*Alpha DaRT is available only through clinical trials.

The Nobel Prize in Physiology or Medicine 2025 was awarded jointly to Mary E. Brunkow, Frederick J. Ramsdell and Shimon Sakaguchi "for their discoveries concerning peripheral immune tolerance"

02/10/2025

After so many years at American Society for Radiation Oncology (ASTRO) (we’ve honestly lost count), our presence at this conference now feels like a long-term relationship.

And just like in a healthy lasting relationship, we feel at home here. We’ve found our place, we’ve built trust, and we share a deep connection with colleagues who feel like family (ok, a professional family). The support and collaboration we experience are the kind that only grow stronger with time.

As this busy and inspiring week comes to a close, we want to say thank you for the partnership, the friendship, and the shared vision. Here’s to many more years of working together to advance the field of . ❤️

25/09/2025

🚀 On Our Way to ASTRO 2025!

Next week our Alpha TAU team is heading to San Francisco for the 67th Annual Meeting of the American Society for Radiation Oncology (ASTRO) 2025. This year’s theme, “Rediscovering Radiation Medicine and Exploring New Indications,” connects directly to what we do every day: pushing the boundaries of cancer treatment.

With Alpha DaRT® - our pioneering intra-tumoral radiotherapy - we’re delivering targeted alpha radiation directly into solid tumors, now available only in clinical trials.

This year, we’re especially proud to share how we’re expanding into new indications:
✅ Treating immunocompromised patients suffering from recurrent SCC.
✅ Advancing toward a new study in Glioblastoma Multiforme (GBM) after FDA IDE approval.
✅ Exploring solutions for pancreatic cancer, one of the toughest unmet needs in oncology.

We’re excited to meet global leaders in radiation oncology, share our progress, and continue redefining the future of radiation medicine.

📍 Come visit us at booth #2417 in San Francisco!